Last reviewed · How we verify
LEO 90100 aerosol foam
LEO 90100 is a topical corticosteroid aerosol foam formulation designed for enhanced skin penetration and coverage in inflammatory skin conditions.
LEO 90100 is a topical corticosteroid aerosol foam formulation designed for enhanced skin penetration and coverage in inflammatory skin conditions. Used for Inflammatory skin conditions (specific indication under investigation in phase 3).
At a glance
| Generic name | LEO 90100 aerosol foam |
|---|---|
| Sponsor | LEO Pharma |
| Drug class | Topical corticosteroid |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
LEO 90100 combines a potent corticosteroid active ingredient with an aerosol foam delivery system that provides improved spreadability, patient convenience, and potentially enhanced bioavailability compared to traditional topical formulations. The foam format allows for easier application to affected areas and may improve adherence in dermatological conditions.
Approved indications
- Inflammatory skin conditions (specific indication under investigation in phase 3)
Common side effects
- Local skin irritation
- Skin atrophy
- Folliculitis
Key clinical trials
- A Study to Investigate Efficacy and Safety With LEO 90100 Compared With Daivobet® Ointment in Adult Chinese Subjects With Stable Plaque Psoriasis (PHASE3)
- Efficacy and Safety of LEO 90100 Foam in Japanese Subjects With Psoriasis Vulgaris (PHASE3)
- LEO 90100 Compared to Vehicle in Subjects With Psoriasis Vulgaris (PHASE3)
- LEO 90100 Aerosol Foam Compared to Calcipotriol Plus Betamethasone Dipropionate Gel in Subjects With Psoriasis Vulgaris (PHASE3)
- Safety and Efficacy of Once Daily Topical Treatment With LEO 90100 Aerosol Foam in Adolescent Subjects With Plaque Psoriasis (PHASE2)
- Patient Insights Following Use of LEO 90100 Aerosol Foam and Daivobet® Gel in Subjects With Psoriasis Vulgaris (PHASE3)
- A Psoriasis Plaque Test Trial With LEO 90100 Compared to Betesil® in Patients With Psoriasis Vulgaris (PHASE2)
- LEO 90100 Compared With Calcipotriol Plus Betamethasone Dipropionate Ointment, LEO 90100 Vehicle and Ointment Vehicle in Subjects With Psoriasis Vulgaris (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LEO 90100 aerosol foam CI brief — competitive landscape report
- LEO 90100 aerosol foam updates RSS · CI watch RSS
- LEO Pharma portfolio CI